Ellie Leick

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

Che-Kai Tsao, MD, discusses the current unmet needs in adjuvant therapy for patients with renal cell carcinoma and how current research is addressing such challenges.

Mohammad Maher Abdul-Hay, MD, discusses current standards for the treatment of patients with acute lymphocytic leukemia.

Ankit Kansagra, MD, discusses the evolving use of CAR T-cell therapy in multiple myeloma and lymphoma.

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Nina Shah, MD, discusses how CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates are being used to treat patients with multiple myeloma.

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Deepu Madduri, MD, discusses ongoing trials examining CAR T-cell therapy in myeloma and the potential to use it in earlier lines of therapy.